Today: 20 March 2026
Subscribe
Browse Category

NASDAQ:MIST 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·

Stock Market Today

  • Brent-WTI Crude Oil Price Spread Hits Decade High Amid Soaring Middle East Demand
    March 20, 2026, 4:27 AM EDT. The price gap between Brent and West Texas Intermediate (WTI) crude oil futures widened to around $14 per barrel Thursday, hitting the largest spread in over a decade. Brent traded at $111.37 a barrel, while WTI was at $97.78. Earlier, the spread neared $20 as Brent rose to $114. Brent, the global seaborne crude benchmark, reflects geopolitical risks and international demand surges, especially from the Middle East and Europe. WTI, priced at a U.S. inland hub in Cushing, Oklahoma, is buffered by domestic production and infrastructure, making it less sensitive to global disruptions. The widened spread highlights increased geopolitical risk premium on Brent amid Middle East tensions impacting oil markets.
Go toTop